Prestige Consumer Healthcare Announces Fiscal 2026 Third Quarter Earnings Results Date and Participation in the ICR Conference
Prestige Consumer Healthcare (NYSE: PBH) will release its fiscal 2026 third quarter earnings on Thursday, February 5, 2026 before market open and will host a conference call the same morning at 8:30 a.m. ET.
Rhea-AI Summary
Prestige Consumer Healthcare (NYSE: PBH) will release its fiscal 2026 third quarter earnings on Thursday, February 5, 2026 before market open and will host a conference call the same morning at 8:30 a.m. ET.
Investors can join a live Internet webcast or register for phone access to receive dial-in details and a unique PIN; joining 10 minutes early is recommended. A conference call replay will be available for approximately one week on the company’s Investor Relations page.
Separately, the company will participate in a fireside chat at the 28th Annual ICR Conference on Tuesday, January 13, 2026 at 9:30 a.m. ET, with a live audio webcast and a replay available later that day.
Positive
- None.
Negative
- None.
Details
News Market Reaction – PBH
On Jan 12, the day this news came out, PBH closed 1.76% above the previous close.
Data tracked by StockTitan Argus for the Jan 12 session.
Key Figures
- Q3 earnings date
- February 5, 2026
- Fiscal 2026 third quarter release before market open
- Earnings call time
- 8:30 a.m. ET
- Fiscal 2026 Q3 conference call start time
- Replay duration
- approximately one week
- Length of Q3 earnings call replay availability
- ICR conference edition
- 28th Annual
- Edition of the ICR Conference PBH will attend
- ICR conference date
- January 13, 2026
- Date of PBH fireside chat at ICR Conference
- ICR fireside time
- 9:30 a.m. ET
- Start time for PBH ICR Conference fireside chat
Historical Context
-
Q2 revenue ahead of outlook and raised EPS guidance supported a modest gain.
-
Scheduling of Q2 and first-half results call produced only a slight price move.
-
Barclays conference participation announcement coincided with a minor share decline.
-
Revenue decline and lowered fiscal 2026 guidance drove a double-digit drop.
-
Announcement of Q1 earnings release and call saw a modest negative reaction.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
TARRYTOWN, N.Y., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (the “Company” or “Prestige”) (NYSE: PBH) today announced it will issue its fiscal 2026 third quarter earnings release on Thursday, February 5, 2026 before the opening of the market. The Company will host a conference call to discuss the results that same morning at 8:30 a.m. ET.
To participate in the live Internet webcast of the conference call, it can be accessed from the Investor Relations page of www.prestigeconsumerhealthcare.com. To participate in the conference call via phone, participants may register for the call here to receive dial-in details and a unique pin. While not required, it is recommended to join 10 minutes prior to the event start.
A conference call replay will be available for approximately one week following completion of the live call and can be accessed on the Company’s Investor Relations page.
ICR Conference
Separately, the company will also participate in a fireside chat at the 28th Annual ICR Conference on Tuesday, January 13, 2026 at 9:30 a.m. ET. Interested parties may access a live audio webcast of this event from the Investor Relations page of www.prestigeconsumerhealthcare.com. A replay of the webcast will be available later that same day.
About Prestige Consumer Healthcare Inc.
Prestige Consumer Healthcare is a leading consumer healthcare products company with sales throughout the U.S. and Canada, Australia, and in certain other international markets. The Company’s diverse portfolio of brands include Monistat® and Summer’s Eve® women's health products, BC® and Goody's® pain relievers, Clear Eyes® and TheraTears® eye care products, DenTek® specialty oral care products, Dramamine® motion sickness treatments, Fleet® enemas and glycerin suppositories, Chloraseptic® and Luden's® sore throat treatments and drops, Compound W® wart treatments, Little Remedies® pediatric over-the-counter products, Boudreaux’s Butt Paste® diaper rash ointments, Nix® lice treatment, Debrox® earwax remover, Gaviscon® antacid in Canada, and Hydralyte® rehydration products and the Fess® line of nasal and sinus care products in Australia. Visit the Company's website at www.prestigeconsumerhealthcare.com.
Source: Prestige Consumer Healthcare Inc.
Investor Relations Contact Phil Terpolilli, CFA, 914-524-6819 irinquiries@prestigebrands.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.